Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171122 | 1.00 | NPC1 (0.68) | NPC1ALDH1A1KMT2ALMNAHTT | |
| SCHEMBL6174893 | 1.00 | NPC1 (0.68) | NPC1ALDH1A1KMT2ALMNAHTT | |
| SCHEMBL6170945 | 0.85 | ALDH1A1 (0.68) | NPC1ALDH1A1KMT2ALMNAHTT | |
| SCHEMBL2164215 | 0.85 | ALDH1A1 (0.68) | NPC1ALDH1A1KMT2ALMNAHTT | |
| SCHEMBL2164884 | 0.85 | ALDH1A1 (0.68) | NPC1ALDH1A1KMT2ALMNAHTT | |
| SCHEMBL13494840 | 0.83 | NPC1 (0.74) | NPC1ALDH1A1KMT2ALMNAHTT | |
| SCHEMBL5644953 | 0.81 | NPC1 (0.88) | NPC1ALDH1A1KMT2ALMNAHTT | |
| SCHEMBL3241450 | 0.79 | ALDH1A1 (0.69) | NPC1ALDH1A1KMT2ALMNAHTT | |
| SCHEMBL16005903 | 0.79 | NPC1 (0.56) | NPC1ALDH1A1KMT2ALMNAHTT | |
| SCHEMBL17439787 | 0.79 | NPC1 (0.56) | NPC1ALDH1A1KMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554245-B1 | PIPERIDINETRIOL DERIVATIVES AS INHIBITORS OF GLYCOSYLCERAMIDSYNTHASE | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-26 | — | — | EP | disclosed |
| EP-1534676-B1 | PIPERIDINETRIOL DERIVATIVES AS INHIBITORS OF GLYCOSYLCERAMIDE SYNTHASE | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-7994198-B2 | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7985760-B2 | Piperidinetriol derivatives as inhibitors of glycosyceramid synthase | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-07-26 | — | — | US | disclosed |
| US-20060111400-A1 | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2006-05-25 | — | — | US | disclosed |
| US-20060058349-A1 | Piperidinetriol derivatives as inhibitors of glycosyceramid synthase | OXFORD GLYCOSCIENCES(UK) LTD (GB) | 2006-03-16 | — | — | US | disclosed |
| EP-1554245-A1 | PIPERIDINETRIOL DERIVATIVES AS INHIBITORS OF GLYCOSYLCERAMIDSYNTHASE | Oxford GlycoSciences (UK) Ltd (GB) | 2005-07-20 | — | — | EP | disclosed |
| EP-1534676-A1 | PIPERIDINETRIOL DERIVATIVES AS INHIBITORS OF GLYCOSYLCERAMIDE SYNTHASE | Oxford GlycoSciences (UK) Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004007453-A1 | PIPERIDINETRIOL DERIVATIVES AS INHIBITORS OF GLYCOSYLCERAMIDE SYNTHASE | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007454-A1 | PIPERIDINETRIOL DERIVATIVES AS INHIBITORS OF GLYCOSYLCERAMIDSYNTHASE | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111400-A1 | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase | GBA1, UGCG, CERS2 | NPC1 130/4885ALDH1A1 790/4885KMT2A 3463/4885 |
| US-20060058349-A1 | Piperidinetriol derivatives as inhibitors of glycosyceramid synthase | CERS2, UGCG, GBA1 | NPC1 205/4885ALDH1A1 894/4885KMT2A 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.